Anti-CLL1 Chimeric Antigen Receptor T Cell Therapy in Children with Relapsed/Refractory Acute Myeloid Leukemia

Scientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia .
[Clinical Cancer Research]
Zhang, H., Wang, P., Li, Z., He, Y., Gan, W., & Jiang, H. (2021). Anti-CLL1 chimeric antigen receptor T cell therapy in children with relapsed/refractory acute myeloid leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-20-4543 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Temporal Multiomic Modeling Reveals a B-Cell Receptor Proliferative Program in Chronic Lymphocytic Leukemia

Using an original ex vivo model of B-cell receptor-induced proliferation of chronic lymphocytic leukemia cells, researchers generated 108 temporal transcriptional and proteomic profiles from one hour up to four days after BCR activation.
[Leukemia]
Schleiss, C., Carapito, R., Fornecker, L.-M., Muller, L., Paul, N., Tahar, O., Pichot, A., Tavian, M., Nicolae, A., Miguet, L., Mauvieux, L., Herbrecht, R., Cianferani, S., Freund, J.-N., Carapito, C., Maumy-Bertrand, M., Bahram, S., Bertrand, F., & Vallat, L. (2021). Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia. Leukemia, 1–12. https://doi.org/10.1038/s41375-021-01221-5 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Improving Outcomes in Chronic Myeloid Leukemia through Harnessing the Immunological Landscape

Scientists focus on immune dysfunction in newly diagnosed chronic myeloid leukemia patients, and the role that tyrosine kinase inhibitors and other therapies have in restoring immune surveillance.
[Leukemia]
Hsieh, Y.-C., Kirschner, K., & Copland, M. (2021). Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia, 1–14. https://doi.org/10.1038/s41375-021-01238-w Cite
Full Article
Bookmark

No account yet? Register

0
Share

CAR-T Cell Therapy: Current Limitations and Potential Strategies

Scientists discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
[Blood Cancer Journal]
Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood Cancer Journal, 11(4), 1–11. https://doi.org/10.1038/s41408-021-00459-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Phase II-Like Murine Trial Identifies Synergy between Dexamethasone and Dasatinib in T-Cell Acute Lymphoblastic Leukemia

Scientists performed an shRNA screen in vitro and in vivo in T-cell acute lymphoblastic leukemia cell lines and patient derived xenograft samples to identify vulnerabilities in the pTCR/TCR pathway and identified a critical role for the kinase LCK in cell proliferation.
[Haematologica]
Shi, Y., Beckett, M. C., Blair, H. J., Tirtakusuma, R., Nakjang, S., Enshaei, A., Halsey, C., Vormoor, J., Heidenreich, O., Krippner-Heidenreich, A., & Delft, F. W. van. (2021). Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica, 106(4), 1056–1066. https://doi.org/10.3324/haematol.2019.241026 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Combining Ibrutinib and Checkpoint Blockade Improves CD8+ T-Cell Function and Control of Chronic Lymphocytic Leukemia in Em-TCL1 Mice

By using the Eµ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia, scientists observed that ibrutinib effectively controled leukemia development, but also resulted in significantly lower numbers of CD8+ effector T-cells, with lower expression of activation markers, as well as impaired proliferation and effector function.
[Haematologica]
Hanna, B. S., Yazdanparast, H., Demerdash, Y., Roessner, P. M., Schulz, R., Lichter, P., Stilgenbauer, S., & Seiffert, M. (2021). Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. Haematologica, 106(4), 968–977. https://doi.org/10.3324/haematol.2019.238154 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Azacitidine for Relapse of Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation, Multicenter PALG Analysis

Researchers conducted retrospective multicenter analysis of patients diagnosed with acute myeloid leukemia or myelodysplastic syndromes who had hematological relapse after allogeneic hematopoietic stem cell transplantation and were treated with azacitidine for this indication.
[European Journal of Haematology]
Drozd‐Sokołowska, J., Karakulska‐Prystupiuk, E., Biecek, P., Kobylińska, K., Piekarska, A., Dutka, M., Waszczuk‐Gajda, A., Mądry, K., Kopińska, A., Gołos, A., Góra‐Tybor, J., Szwedyk, P., Bołkun, Ł., Czyż, A., Giebel, S., Basak, G. W., & Dwilewicz‐Trojaczek, J. (n.d.). Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis. European Journal of Haematology, n/a(n/a). https://doi.org/https://doi.org/10.1111/ejh.13628 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Outcome of Haploidentical versus Matched Sibling Donors in Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Investigators retrospectively analyzed adult patients with acute lymphoblastic leukemia who underwent their first allogeneic stem cell transplantation in first or second complete remission between 2012 and 2018, either from a T cell replete Haplo or matched sibling donor donor.
[Journal of Hematology & Oncology]
Nagler, A., Labopin, M., Houhou, M., Aljurf, M., Mousavi, A., Hamladji, R.-M., Al Zahrani, M., Bondarenko, S., Arat, M., Angelucci, E., Koc, Y., Gülbas, Z., Sica, S., Bourhis, J. H., Canaani, J., Brissot, E., Giebel, S., & Mohty, M. (2021). Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Journal of Hematology & Oncology, 14(1), 53. https://doi.org/10.1186/s13045-021-01065-7 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia

Scientists found that leukemic stem cells in chronic myelomonocytic leukemia resided in a CD34+/CD38 fraction of the malignant clone.
[Leukemia]
Eisenwort, G., Sadovnik, I., Keller, A., Ivanov, D., Peter, B., Berger, D., Stefanzl, G., Bauer, K., Slavnitsch, K., Greiner, G., Gleixner, K. V., Sperr, W. R., Willmann, M., Sill, H., Bettelheim, P., Geissler, K., Deininger, M., Rülicke, T., & Valent, P. (2021). Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. Leukemia, 1–12. https://doi.org/10.1038/s41375-021-01227-z Cite
Abstract
Bookmark

No account yet? Register

0
Share

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage II of Phase II Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.
[Bio-Path Holdings, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Kite Submits Supplemental Biologics License Application to US Food and Drug Administration for Tecartus® in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
[Kite (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share
Share